Abstract: Silylalkyloxyaryl compounds useful as anti-cancer agents. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of melanoma, colon, neuroblastoma, bladder, breast, lung, pancreatic, melanoma, sarcoma, lymphoma or gastric cancer.

Abstract: Silylalkyloxyaryl compounds useful as anti-cancer agents. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of melanoma, colon, neuroblastoma, bladder, breast, lung, pancreatic, melanoma, sarcoma, lymphoma or gastric cancer.

Abstract: The subject of the invention is a compound of antiplasmid effect having the general formula I wherein Q means: &bgr;-picolinyl-methoiodide or 1-methyl-4-piperidyl or 3-(4′-fluorophenyl)-2,2-dimethyl-2-sila-propyloxy or 2-dimethyl-amino-ethyl-methoiodide group and Y means: 2,2-dimethyl-2-sila-hexyloxy or 3-(4′-fluorophenyl)-2,2-dimethyl-2-sila-propyloxy or 5-(4′-fluorophenyl)-4,4-dimethyl-4-sila-pentyloxy or 3-trimethylsilil-propyloxy group. The subject of the invention is the method for producing of the above compound. The subject of the invention is also the pharmaceutical composition of antiplasmid effect, which contains the above composition and the method of producing thereof.

Abstract: The subject of the invention is a compound of antiplasmid effect of the general formula O(OQ)C—C6H4Y wherein Q means: &bgr;-picolinyl-methoiodide or 1-methyl-4-piperydyl or 3-(4′-fluorophenyl)-2,2-dimethyl-2-sila-propyloxy or 2-dimethyl-amino-ethyl-methoiodide group and Y means: 2,2-dimethyl-2-sila-hexyloxy or 3-(4′-fluorophenyl)-2,2-dimethyl-2-sila-propyloxy or 5-(4′-fluorophenyl)-4,4-dimethyl-4-sila-pentyloxy or 3-trimethylsilil-propyloxy group. The subject of the invention is the method for producing of the above compound. The subject of the invention is also the pharmaceutical composition of antiplasmid effect, which contains the above composition and the method of producing thereof.

Abstract: A method of treating a mammalian subject for Parkinson's disease or to provide a central muscle relaxant effect, which comprises the step of administering to the mammalian subject in need of the treatment, a therapeutically effective amount of a compound of the Formula (I) ##STR1## wherein m is 1,2 or 3;R.sub.1 and R.sub.2 each independently stand for hydrogen, C.sub.1 to C.sub.4 straight or branched chain alkyl, C.sub.1 to C.sub.4 alkoxy, C.sub.5 to C.sub.7 cycloalkyl, or halogen; andB is a 5- or 6-membered saturated or unsaturated heterocyclic group containing a nitrogen heteroatom, the heterocyclic group being bound through its heterocyclic nitrogen atom to the remainder of the compound, and which can contain one or two additional heteroatoms selected from the group consisting of an oxygen heteroatom, a sulfur heteroatom, and one or two additional nitrogen heteroatoms, which may be as an .dbd.N--, --NH-- or --NR-- group, where R is a C.sub.1 to C.sub.5 alkyl or C.sub.1 to C.sub.

Abstract: A method of treating a mammalian subject for Parkinson's disease or to provide a central muscle relaxant effect, which comprises the step of administering to the mammalian subject in need of the treatment, a therapeutically effective amount of a compound of the Formula (I) ##STR1## wherein m is 1,2 or 3;R.sub.1 and R.sub.2 each independently stand for hydrogen, C.sub.1 to C.sub.4 straight or branched chain alkyl, C.sub.1 to C.sub.4 alkoxy, C.sub.5 to C.sub.7 cycloalkyl, or halogen; andB is a 5- or 6-membered saturated or unsaturated heterocyclic group containing a nitrogen heteroatom, the heterocyclic group being bound through its heterocyclic nitrogen atom to the remainder of the compound, and which can contain one or two additional heteroatoms selected form the group consisting of an oxygen heteroatom, a sulfur heteroatom, and one or two additional nitrogen heteroatoms, which may be as an .dbd.N--, --NH-- or --NR-- group, where R is a C.sub.1 to C.sub.5 alkyl or C.sub.1 to C.sub.